![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Roche Receives CE Mark for Elecsys Cancer Test
Roche Receives CE Mark for Elecsys Cancer Test
![CE mark](https://www.fdanews.com/ext/resources/images/ce-mark.gif?t=1627682539&width=430)
April 9, 2021
Roche has received CE mark certification for its Elecsys anti-p53 immunoassay, a test used to diagnose various types of cancer.
The Elecsys test is used for the in vitro quantitative determination of anti-p53 antibodies in patients to aid physicians in diagnosis of esophageal cancer, bowel cancer and breast cancer.
Screening for anti-p53 antibodies can help to diagnose cancer earlier, increasing the chances that a patient responds to treatment. It can also help to monitor cancer cells that persist in patients after treatment.
Upcoming Events
-
21Oct